Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. B. Lin, J. J. Lee, H. C. Sun (Hualien, Taiwan). Improved treatment outcome of MDR-TB in Eastern Taiwan: Reducing default rate by DOTS Plus. Eur Respir J 2013; 42: Suppl. 57, 4692

Member's Comments

No comment yet.

Related content which might interest you: Clinical profile of MDR-TB patients and their early response to DOTS PLUS: An Indian perspective Source: Annual Congress 2013 –Tuberculosis: clinical aspects Year: 2013 National evidence on the inefficiency of an inpatient model of tuberculosis management in Eastern Europe Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 Trend in TB control in Republic of Moldova: High MDRTB burden country Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014 MDR TB treatment results of GFATM program implementation in Tomsk, Russia Source: International Congress 2015 – Management of TB: a patient focus Year: 2015 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Effectiveness of national standardized and WHO regimens and risk factors of unfavorable outcomes in treatment of patients with MDR-TB in Novosibirsk Oblast, Russian Federation Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014 Gene-Xpert for rapid detection of MDR-TB in re-treatment cases;a comparison with standard culture and DST Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015 Study on drug sensitivity patterns in tuberculosis in tertiary care in Mumbai Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Failure predictors when treating MDR-TB Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Experience of managing TB/HIV infection in a regional UK center over a 5 year period Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016 Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 The risk of default in TB patients in the Russian Federation Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2 Year: 2014 Out-patient MDR-TB care in Moldova Source: International Congress 2015 – Management of TB: a patient focus Year: 2015 Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Changing prevalence of MDR TB and XDR TB in a tertiary care hospital in India Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I Year: 2013 Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Healing predictors when treating MDR-TB Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015